## IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Original): A heterocyclic compound represented by the formula I:

wherein X represents nitrogen atom or CH; Y represents  $C_1$ - $C_6$  alkyl;  $R_1$  represents morpholino (which may be substituted with one to four  $C_1$ - $C_6$  alkyl); and  $R_2$  and  $R_3$  each represent hydrogen atom or  $C_1$ - $C_6$  alkyl.

Claim 2 (Currently Amended): A compound as claimed in claim 1, wherein X is CH, Y being is methyl, R<sub>1</sub> being is morpholino, and each of R<sub>2</sub> and R<sub>3</sub> being is methyl.

Claim 3 (Original): A compound as claimed in claim 1, wherein the compound of the formula I is 2-(2-difluoromethyl-4-methoxybenzimidazol-1-yl)-4-(cis-2,6-dimethylmorpholino)-6-morpholinopyrimidine.

Claim 4 (Original): A compound as claimed in claim 1, wherein the compound of the formula I is 2-(2-difluoromethyl-4-methoxybenzimidazol-1-yl)-4-(2,2-dimethylmorpholino)-6-morpholinopyrimidine.

Docket No. 295483US Preliminary Amendment

Claim 5 (Currently Amended): An anti-malignant-tumor agent containing at least one compound as claimed in claims 1 to 4 claim 1 as an effective component.

Claim 6 (Currently Amended): A pharmaceutical composition including at least one compound as claimed in claims 1 to 4 claim 1 as an anti-malignant-tumor active component together with pharmaceutically acceptable diluent or carrier.